Sanofi

4Q Revenues: €8.9 billion (+3%)

4Q Earnings: €811 million (+130%)

FY Revenues: €33.8 billion (-1%)

FY Earnings: €4.8 billion (+9%)

Comments: Sanofi Genzyme (Specialty Care) sales were €1.3 billion in the quarter, up 13% driven by multiple sclerosis products. Sanofi Pasteur GBU revenue grew 4% to €1.4 billion due to strong pediatric combination franchise sales. Diabetes and Cardiovascular GBU sales were €1.7 billion up 4%, with diabetes franchise sales up 2%. Rare Disease sales increased 10% to €716 million driven by the accrual of patients worldwide and strong performance of the franchise in Emerging Markets. Oncology sales were down 4% to €369 million. Consumer Healthcare sales increased 3% to €834 million driven by the performance in Europe. Generics sales were flat at €468 million. Results in the quarter include discontinued operations of the Animal Health business.